First Time Loading...

Relay Therapeutics Inc
NASDAQ:RLAY

Watchlist Manager
Relay Therapeutics Inc Logo
Relay Therapeutics Inc
NASDAQ:RLAY
Watchlist
Price: 7.06 USD 0.28% Market Closed
Updated: May 7, 2024
Section:
 

Wall Street
Price Targets

RLAY Price Targets Summary
Relay Therapeutics Inc

Wall Street analysts forecast RLAY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RLAY is 23.52 USD with a low forecast of 10.71 USD and a high forecast of 34.65 USD.

RLAY Lowest Forecast
Wall Street Target
10.71 USD
52% Upside
RLAY Average Forecast
Wall Street Target
23.52 USD
233% Upside
RLAY Highest Forecast
Wall Street Target
34.65 USD
391% Upside
Lowest
Price Target
10.71 USD
52% Upside
Average
Price Target
23.52 USD
233% Upside
Highest
Price Target
34.65 USD
391% Upside

RLAY Last Price Targets
Relay Therapeutics Inc

The latest public price target was made on May 6, 2024 by Matt Biegler from Oppenheimer , who expects RLAY stock to rise by 254% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Matt Biegler
Oppenheimer
25 USD
Upside 254%
1 day ago
May 6, 2024
Relay Therapeutics (RLAY) PT Lowered to $25 at Oppenheimer
StreetInsider
Akash Tewari
Jefferies
12.5 USD
Upside 77%
1 year ago
Apr 20, 2023
Jefferies Upgrades Relay Therapeutics (RLAY ) to Hold
StreetInsider
Unknown Analyst
Oppenheimer
33 USD
Upside 367%
1 year ago
Feb 3, 2023
Oppenheimer Initiates Coverage On Relay Therapeutics with Outperform Rating, Announces Price Target of $33
Benzinga
Matt Biegler
Oppenheimer
Price Target 25 USD
Upside/Downside 254%
View Source
Akash Tewari
Jefferies
Price Target 12.5 USD
Upside/Downside 77%
View Source
Unknown Analyst
Oppenheimer
Price Target 33 USD
Upside/Downside 367%
View Source
Relay Therapeutics Inc Competitors:
Price Targets
AVCT
Avacta Group PLC
107% Upside
PROB
Probi AB
54% Upside
M
086900
Medy Tox Inc
74% Upside
M
235980
MedPacto Inc
146% Upside
AVCT
Avacta Group PLC
107% Upside
PROB
Probi AB
54% Upside
M
086900
Medy Tox Inc
74% Upside
M
235980
MedPacto Inc
146% Upside
VRTX
Vertex Pharmaceuticals Inc
18% Upside
D
002030
Daan Gene Co Ltd
103% Upside
300639
Guangdong Hybribio Biotech Co Ltd
509% Upside
GTH
Genetron Holdings Ltd
67% Downside

Revenue
Forecast

Revenue Estimate
Relay Therapeutics Inc

The compound annual growth rate of Relay Therapeutics Inc's revenue for the next 3 years is -45%.

N/A
Past Growth
-45%
Estimated Growth
Estimates Accuracy
-28%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Relay Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Relay Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-24%
Average Miss
What are analyst estimates?

See Also

Summary
RLAY intrinsic value, competitors valuation, and company profile.
DCF Valuation
RLAY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RLAY stock valuation using valuation multiples.
Wall Street Estimates
RLAY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RLAY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RLAY's stock price target?
Price Target
23.52 USD

According to Wall Street analysts, the average 1-year price target for RLAY is 23.52 USD with a low forecast of 10.71 USD and a high forecast of 34.65 USD.

What is Relay Therapeutics Inc's Revenue forecast?
Projected CAGR
-45%

The compound annual growth rate of Relay Therapeutics Inc's revenue for the next 3 years is -45%.

ALPHA SPREAD
Join more than 135,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.